subject inclusion criteria in PK and stat and BE conclusion [Regulatives / Guidelines]

posted by Ramesh Ramalingam  – India, 2017-09-05 07:35  – Posting: # 17776
Views: 5,886

Dear All,

I have more doubt on subject inclusion criteria for pharmacokinetic and statistical analysis in fully replicate (Including NTI drugs) and partial replicate design BE studies. could you please suggest the subject inclusion criteria for PK and stat analysis (including who's data can be considered for BE)? Also, How many treatment periods subject should be completed in the study?



Regards,
Ramesh Ramalingam

Complete thread:

Activity
 Mix view
Bioequivalence and Bioavailability Forum |  Admin contact
19,514 posts in 4,141 threads, 1,336 registered users;
online 5 (0 registered, 5 guests [including 4 identified bots]).
Forum time (Europe/Vienna): 04:57 CEST

I have not failed 700 times. I have not failed once.
I have succeeded in proving
that those 700 ways will not work.    Thomas Alva Edison

The BIOEQUIVALENCE / BIOAVAILABILITY FORUM is hosted by
BEBAC Ing. Helmut Schütz
HTML5